This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Justin Maxhimer: Innovator in Radioprotection
Introduction
Justin Maxhimer is a notable inventor based in Elkridge, MD (US). He has made significant contributions to the field of radioprotection through his innovative research and patent work. His discoveries have the potential to enhance the safety and efficacy of radiation therapies.
Latest Patents
Justin Maxhimer holds a patent for "Radioprotectants targeting thrombospondin-1 and CD47." This patent describes the groundbreaking discovery that cell and tissue survival can be significantly improved following radiation exposure by inhibiting the interaction between TSP-1 and CD47. The patent outlines the use of antisense molecules, peptides, and antibodies as radioprotectant agents. These agents are designed to minimize, reduce, and prevent tissue damage from both intentional and accidental radiation exposure. Additionally, they can enhance the therapeutic efficacy of radiation therapies by protecting non-target tissues from incidental radiation damage and increasing tumor ablation following radiation treatment.
Career Highlights
Justin Maxhimer is affiliated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His work in this esteemed organization underscores his commitment to advancing health and safety through innovative research.
Collaborations
Throughout his career, Justin has collaborated with esteemed colleagues, including Jeffrey S. Isenberg and David D. Roberts. These collaborations have further enriched his research and contributed to the development of effective radioprotectant agents.
Conclusion
In summary, Justin Maxhimer is a pioneering inventor whose work in radioprotection has the potential to transform the landscape of radiation therapy. His innovative approaches and patented discoveries are vital for enhancing patient safety and treatment outcomes.